nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Imiquimod—skin cancer	0.095	0.292	CbGbCtD
Orlistat—CYP3A4—Temozolomide—skin cancer	0.095	0.292	CbGbCtD
Orlistat—CYP3A4—Vismodegib—skin cancer	0.0659	0.202	CbGbCtD
Orlistat—CYP3A4—Vemurafenib—skin cancer	0.0521	0.16	CbGbCtD
Orlistat—CYP3A4—Docetaxel—skin cancer	0.0179	0.0548	CbGbCtD
Orlistat—PLA2G7—nipple—skin cancer	0.0149	0.0868	CbGeAlD
Orlistat—ABHD16A—nipple—skin cancer	0.0139	0.0815	CbGeAlD
Orlistat—ABHD12—nipple—skin cancer	0.0131	0.0764	CbGeAlD
Orlistat—FASN—Sorafenib—Vismodegib—skin cancer	0.0127	1	CbGdCrCtD
Orlistat—PLA2G7—Peptide hormone metabolism—EXOC2—skin cancer	0.0115	0.122	CbGpPWpGaD
Orlistat—FASN—nipple—skin cancer	0.011	0.0641	CbGeAlD
Orlistat—PLA2G7—connective tissue—skin cancer	0.0105	0.0616	CbGeAlD
Orlistat—DAGLA—head—skin cancer	0.00991	0.0579	CbGeAlD
Orlistat—PNLIP—connective tissue—skin cancer	0.00926	0.0542	CbGeAlD
Orlistat—PLA2G7—mammalian vulva—skin cancer	0.00867	0.0507	CbGeAlD
Orlistat—ABHD16A—mammalian vulva—skin cancer	0.00814	0.0476	CbGeAlD
Orlistat—PLA2G7—lymphoid tissue—skin cancer	0.0077	0.045	CbGeAlD
Orlistat—ABHD12—mammalian vulva—skin cancer	0.00763	0.0446	CbGeAlD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—KRT5—skin cancer	0.00753	0.0794	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—KRT14—skin cancer	0.007	0.0739	CbGpPWpGaD
Orlistat—PNLIP—female reproductive system—skin cancer	0.00653	0.0382	CbGeAlD
Orlistat—FASN—mammalian vulva—skin cancer	0.0064	0.0374	CbGeAlD
Orlistat—PNLIP—head—skin cancer	0.00546	0.0319	CbGeAlD
Orlistat—DAGLB—lymph node—skin cancer	0.00538	0.0315	CbGeAlD
Orlistat—PLA2G4A—nipple—skin cancer	0.00527	0.0308	CbGeAlD
Orlistat—PLA2G7—lymph node—skin cancer	0.00435	0.0254	CbGeAlD
Orlistat—ABHD16A—lymph node—skin cancer	0.00408	0.0238	CbGeAlD
Orlistat—ABHD12—lymph node—skin cancer	0.00382	0.0223	CbGeAlD
Orlistat—PLA2G4A—connective tissue—skin cancer	0.00374	0.0218	CbGeAlD
Orlistat—FASN—lymph node—skin cancer	0.00321	0.0188	CbGeAlD
Orlistat—PLA2G4A—mammalian vulva—skin cancer	0.00308	0.018	CbGeAlD
Orlistat—PLA2G4A—female reproductive system—skin cancer	0.00264	0.0154	CbGeAlD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.00225	0.0237	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.00218	0.023	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—EXOC2—skin cancer	0.00218	0.023	CbGpPWpGaD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00204	0.0216	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—RASA1—skin cancer	0.00178	0.0188	CbGpPWpGaD
Orlistat—PLA2G4A—lymph node—skin cancer	0.00154	0.00901	CbGeAlD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—skin cancer	0.00134	0.0142	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00126	0.0133	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—RASA1—skin cancer	0.00125	0.0132	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RHOU—skin cancer	0.00124	0.0131	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RHOU—skin cancer	0.00124	0.0131	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RHOU—skin cancer	0.00103	0.0108	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PTCH2—skin cancer	0.00102	0.0108	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTCH2—skin cancer	0.00102	0.0108	CbGpPWpGaD
Orlistat—Haemorrhage—Bleomycin—skin cancer	0.00102	0.00257	CcSEcCtD
Orlistat—Infection—Imiquimod—skin cancer	0.00101	0.00255	CcSEcCtD
Orlistat—Nervous system disorder—Imiquimod—skin cancer	0.000996	0.00252	CcSEcCtD
Orlistat—Upper respiratory tract infection—Temozolomide—skin cancer	0.000994	0.00251	CcSEcCtD
Orlistat—Skin disorder—Imiquimod—skin cancer	0.000986	0.00249	CcSEcCtD
Orlistat—Hyperhidrosis—Imiquimod—skin cancer	0.000982	0.00248	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—FOXO4—skin cancer	0.000961	0.0101	CbGpPWpGaD
Orlistat—Infestation NOS—Temozolomide—skin cancer	0.000954	0.00241	CcSEcCtD
Orlistat—Infestation—Temozolomide—skin cancer	0.000954	0.00241	CcSEcCtD
Orlistat—Depression—Temozolomide—skin cancer	0.000951	0.0024	CcSEcCtD
Orlistat—Hepatitis—Dactinomycin—skin cancer	0.000947	0.00239	CcSEcCtD
Orlistat—Body temperature increased—Vemurafenib—skin cancer	0.000941	0.00238	CcSEcCtD
Orlistat—Pharyngitis—Dactinomycin—skin cancer	0.00094	0.00238	CcSEcCtD
Orlistat—Neuropathy peripheral—Temozolomide—skin cancer	0.000935	0.00236	CcSEcCtD
Orlistat—Urinary tract infection—Temozolomide—skin cancer	0.000927	0.00234	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000925	0.00234	CcSEcCtD
Orlistat—Insomnia—Imiquimod—skin cancer	0.000918	0.00232	CcSEcCtD
Orlistat—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000916	0.00232	CcSEcCtD
Orlistat—Hepatic failure—Docetaxel—skin cancer	0.000916	0.00232	CcSEcCtD
Orlistat—Paraesthesia—Imiquimod—skin cancer	0.000912	0.0023	CcSEcCtD
Orlistat—Hepatobiliary disease—Temozolomide—skin cancer	0.000902	0.00228	CcSEcCtD
Orlistat—Alopecia—Bleomycin—skin cancer	0.000897	0.00227	CcSEcCtD
Orlistat—Sinusitis—Temozolomide—skin cancer	0.000895	0.00226	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000895	0.00944	CbGpPWpGaD
Orlistat—Dyspepsia—Imiquimod—skin cancer	0.000894	0.00226	CcSEcCtD
Orlistat—Decreased appetite—Imiquimod—skin cancer	0.000883	0.00223	CcSEcCtD
Orlistat—Infestation NOS—Fluorouracil—skin cancer	0.000879	0.00222	CcSEcCtD
Orlistat—Infestation—Fluorouracil—skin cancer	0.000879	0.00222	CcSEcCtD
Orlistat—Hypersensitivity—Vemurafenib—skin cancer	0.000877	0.00222	CcSEcCtD
Orlistat—Gastrointestinal disorder—Imiquimod—skin cancer	0.000877	0.00222	CcSEcCtD
Orlistat—Fatigue—Imiquimod—skin cancer	0.000875	0.00221	CcSEcCtD
Orlistat—Menopausal symptoms—Docetaxel—skin cancer	0.000873	0.00221	CcSEcCtD
Orlistat—CYP3A4—female reproductive system—skin cancer	0.000869	0.00508	CbGeAlD
Orlistat—Pain—Imiquimod—skin cancer	0.000868	0.00219	CcSEcCtD
Orlistat—Neuropathy peripheral—Fluorouracil—skin cancer	0.000862	0.00218	CcSEcCtD
Orlistat—Dermatitis bullous—Docetaxel—skin cancer	0.000861	0.00218	CcSEcCtD
Orlistat—Haemoglobin—Temozolomide—skin cancer	0.000861	0.00218	CcSEcCtD
Orlistat—Haemorrhage—Temozolomide—skin cancer	0.000856	0.00217	CcSEcCtD
Orlistat—Hepatitis—Temozolomide—skin cancer	0.000856	0.00217	CcSEcCtD
Orlistat—Urinary tract infection—Fluorouracil—skin cancer	0.000854	0.00216	CcSEcCtD
Orlistat—Asthenia—Vemurafenib—skin cancer	0.000854	0.00216	CcSEcCtD
Orlistat—Pharyngitis—Temozolomide—skin cancer	0.00085	0.00215	CcSEcCtD
Orlistat—Urinary tract disorder—Temozolomide—skin cancer	0.000846	0.00214	CcSEcCtD
Orlistat—Oedema peripheral—Temozolomide—skin cancer	0.000844	0.00213	CcSEcCtD
Orlistat—Pruritus—Vemurafenib—skin cancer	0.000842	0.00213	CcSEcCtD
Orlistat—Urethral disorder—Temozolomide—skin cancer	0.00084	0.00212	CcSEcCtD
Orlistat—Alopecia—Dactinomycin—skin cancer	0.000837	0.00212	CcSEcCtD
Orlistat—Feeling abnormal—Imiquimod—skin cancer	0.000837	0.00212	CcSEcCtD
Orlistat—Gastrointestinal pain—Imiquimod—skin cancer	0.00083	0.0021	CcSEcCtD
Orlistat—Sinusitis—Fluorouracil—skin cancer	0.000825	0.00208	CcSEcCtD
Orlistat—Ill-defined disorder—Bleomycin—skin cancer	0.00082	0.00207	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—MC1R—skin cancer	0.000815	0.0086	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—MC1R—skin cancer	0.000815	0.0086	CbGpPWpGaD
Orlistat—Diarrhoea—Vemurafenib—skin cancer	0.000815	0.00206	CcSEcCtD
Orlistat—Urticaria—Imiquimod—skin cancer	0.000807	0.00204	CcSEcCtD
Orlistat—Body temperature increased—Imiquimod—skin cancer	0.000803	0.00203	CcSEcCtD
Orlistat—Abdominal pain—Imiquimod—skin cancer	0.000803	0.00203	CcSEcCtD
Orlistat—Malaise—Bleomycin—skin cancer	0.000797	0.00201	CcSEcCtD
Orlistat—Haemoglobin—Fluorouracil—skin cancer	0.000793	0.002	CcSEcCtD
Orlistat—Haemorrhage—Fluorouracil—skin cancer	0.000789	0.00199	CcSEcCtD
Orlistat—Dizziness—Vemurafenib—skin cancer	0.000787	0.00199	CcSEcCtD
Orlistat—Pharyngitis—Fluorouracil—skin cancer	0.000783	0.00198	CcSEcCtD
Orlistat—Immune system disorder—Temozolomide—skin cancer	0.000774	0.00196	CcSEcCtD
Orlistat—Mediastinal disorder—Temozolomide—skin cancer	0.000772	0.00195	CcSEcCtD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000772	0.00814	CbGpPWpGaD
Orlistat—Cough—Bleomycin—skin cancer	0.000771	0.00195	CcSEcCtD
Orlistat—FASN—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.000767	0.0081	CbGpPWpGaD
Orlistat—Ill-defined disorder—Dactinomycin—skin cancer	0.000765	0.00193	CcSEcCtD
Orlistat—Vomiting—Vemurafenib—skin cancer	0.000757	0.00191	CcSEcCtD
Orlistat—Alopecia—Temozolomide—skin cancer	0.000757	0.00191	CcSEcCtD
Orlistat—Dry skin—Docetaxel—skin cancer	0.000755	0.00191	CcSEcCtD
Orlistat—Chest pain—Bleomycin—skin cancer	0.000752	0.0019	CcSEcCtD
Orlistat—Myalgia—Bleomycin—skin cancer	0.000752	0.0019	CcSEcCtD
Orlistat—Abdominal pain upper—Docetaxel—skin cancer	0.000752	0.0019	CcSEcCtD
Orlistat—Rash—Vemurafenib—skin cancer	0.000751	0.0019	CcSEcCtD
Orlistat—Mental disorder—Temozolomide—skin cancer	0.00075	0.0019	CcSEcCtD
Orlistat—Dermatitis—Vemurafenib—skin cancer	0.00075	0.0019	CcSEcCtD
Orlistat—Hypersensitivity—Imiquimod—skin cancer	0.000748	0.00189	CcSEcCtD
Orlistat—Headache—Vemurafenib—skin cancer	0.000746	0.00189	CcSEcCtD
Orlistat—Malnutrition—Temozolomide—skin cancer	0.000746	0.00188	CcSEcCtD
Orlistat—Breast disorder—Docetaxel—skin cancer	0.000744	0.00188	CcSEcCtD
Orlistat—Discomfort—Bleomycin—skin cancer	0.000743	0.00188	CcSEcCtD
Orlistat—Malaise—Dactinomycin—skin cancer	0.000743	0.00188	CcSEcCtD
Orlistat—Cramp muscle—Docetaxel—skin cancer	0.000741	0.00187	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—MC1R—skin cancer	0.00074	0.00781	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MC1R—skin cancer	0.00074	0.00781	CbGpPWpGaD
Orlistat—Dysgeusia—Temozolomide—skin cancer	0.00073	0.00185	CcSEcCtD
Orlistat—Asthenia—Imiquimod—skin cancer	0.000729	0.00184	CcSEcCtD
Orlistat—Oedema—Bleomycin—skin cancer	0.000721	0.00182	CcSEcCtD
Orlistat—Anaphylactic shock—Bleomycin—skin cancer	0.000721	0.00182	CcSEcCtD
Orlistat—Back pain—Temozolomide—skin cancer	0.000721	0.00182	CcSEcCtD
Orlistat—Pruritus—Imiquimod—skin cancer	0.000718	0.00182	CcSEcCtD
Orlistat—Infection—Bleomycin—skin cancer	0.000717	0.00181	CcSEcCtD
Orlistat—Nausea—Vemurafenib—skin cancer	0.000707	0.00179	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—RASA1—skin cancer	0.000703	0.00742	CbGpPWpGaD
Orlistat—Vision blurred—Temozolomide—skin cancer	0.000703	0.00178	CcSEcCtD
Orlistat—Myalgia—Dactinomycin—skin cancer	0.000702	0.00177	CcSEcCtD
Orlistat—Bronchospasm—Docetaxel—skin cancer	0.0007	0.00177	CcSEcCtD
Orlistat—Alopecia—Fluorouracil—skin cancer	0.000697	0.00176	CcSEcCtD
Orlistat—Diarrhoea—Imiquimod—skin cancer	0.000695	0.00176	CcSEcCtD
Orlistat—Discomfort—Dactinomycin—skin cancer	0.000693	0.00175	CcSEcCtD
Orlistat—Ill-defined disorder—Temozolomide—skin cancer	0.000692	0.00175	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—skin cancer	0.000682	0.0072	CbGpPWpGaD
Orlistat—Angioedema—Temozolomide—skin cancer	0.000681	0.00172	CcSEcCtD
Orlistat—Oedema—Dactinomycin—skin cancer	0.000673	0.0017	CcSEcCtD
Orlistat—Malaise—Temozolomide—skin cancer	0.000672	0.0017	CcSEcCtD
Orlistat—Dizziness—Imiquimod—skin cancer	0.000671	0.0017	CcSEcCtD
Orlistat—Vertigo—Temozolomide—skin cancer	0.00067	0.00169	CcSEcCtD
Orlistat—Infection—Dactinomycin—skin cancer	0.000668	0.00169	CcSEcCtD
Orlistat—Palpitations—Temozolomide—skin cancer	0.000659	0.00167	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000657	0.00166	CcSEcCtD
Orlistat—Cough—Temozolomide—skin cancer	0.000651	0.00164	CcSEcCtD
Orlistat—Paraesthesia—Bleomycin—skin cancer	0.000648	0.00164	CcSEcCtD
Orlistat—Vision blurred—Fluorouracil—skin cancer	0.000647	0.00164	CcSEcCtD
Orlistat—Convulsion—Temozolomide—skin cancer	0.000646	0.00163	CcSEcCtD
Orlistat—Vomiting—Imiquimod—skin cancer	0.000646	0.00163	CcSEcCtD
Orlistat—Rash—Imiquimod—skin cancer	0.00064	0.00162	CcSEcCtD
Orlistat—Dermatitis—Imiquimod—skin cancer	0.00064	0.00162	CcSEcCtD
Orlistat—Headache—Imiquimod—skin cancer	0.000636	0.00161	CcSEcCtD
Orlistat—Myalgia—Temozolomide—skin cancer	0.000635	0.0016	CcSEcCtD
Orlistat—Infestation—Docetaxel—skin cancer	0.000634	0.0016	CcSEcCtD
Orlistat—Infestation NOS—Docetaxel—skin cancer	0.000634	0.0016	CcSEcCtD
Orlistat—Anxiety—Temozolomide—skin cancer	0.000633	0.0016	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00063	0.00159	CcSEcCtD
Orlistat—Discomfort—Temozolomide—skin cancer	0.000627	0.00159	CcSEcCtD
Orlistat—Decreased appetite—Bleomycin—skin cancer	0.000627	0.00159	CcSEcCtD
Orlistat—Renal failure—Docetaxel—skin cancer	0.000624	0.00158	CcSEcCtD
Orlistat—Neuropathy peripheral—Docetaxel—skin cancer	0.000622	0.00157	CcSEcCtD
Orlistat—Dry mouth—Temozolomide—skin cancer	0.000621	0.00157	CcSEcCtD
Orlistat—Pain—Bleomycin—skin cancer	0.000617	0.00156	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000613	0.00155	CcSEcCtD
Orlistat—Oedema—Temozolomide—skin cancer	0.000608	0.00154	CcSEcCtD
Orlistat—Anaphylactic shock—Temozolomide—skin cancer	0.000608	0.00154	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—PTCH2—skin cancer	0.000605	0.00638	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTCH2—skin cancer	0.000605	0.00638	CbGpPWpGaD
Orlistat—Infection—Temozolomide—skin cancer	0.000605	0.00153	CcSEcCtD
Orlistat—Nausea—Imiquimod—skin cancer	0.000603	0.00152	CcSEcCtD
Orlistat—Hepatobiliary disease—Docetaxel—skin cancer	0.0006	0.00152	CcSEcCtD
Orlistat—Nervous system disorder—Temozolomide—skin cancer	0.000597	0.00151	CcSEcCtD
Orlistat—Convulsion—Fluorouracil—skin cancer	0.000595	0.0015	CcSEcCtD
Orlistat—Feeling abnormal—Bleomycin—skin cancer	0.000594	0.0015	CcSEcCtD
Orlistat—Skin disorder—Temozolomide—skin cancer	0.000591	0.00149	CcSEcCtD
Orlistat—Hyperhidrosis—Temozolomide—skin cancer	0.000588	0.00149	CcSEcCtD
Orlistat—Chest pain—Fluorouracil—skin cancer	0.000585	0.00148	CcSEcCtD
Orlistat—Myalgia—Fluorouracil—skin cancer	0.000585	0.00148	CcSEcCtD
Orlistat—Decreased appetite—Dactinomycin—skin cancer	0.000585	0.00148	CcSEcCtD
Orlistat—Fatigue—Dactinomycin—skin cancer	0.00058	0.00147	CcSEcCtD
Orlistat—Discomfort—Fluorouracil—skin cancer	0.000578	0.00146	CcSEcCtD
Orlistat—Pain—Dactinomycin—skin cancer	0.000575	0.00145	CcSEcCtD
Orlistat—Urticaria—Bleomycin—skin cancer	0.000573	0.00145	CcSEcCtD
Orlistat—Haemoglobin—Docetaxel—skin cancer	0.000572	0.00145	CcSEcCtD
Orlistat—Body temperature increased—Bleomycin—skin cancer	0.00057	0.00144	CcSEcCtD
Orlistat—Haemorrhage—Docetaxel—skin cancer	0.00057	0.00144	CcSEcCtD
Orlistat—Hepatitis—Docetaxel—skin cancer	0.00057	0.00144	CcSEcCtD
Orlistat—Pharyngitis—Docetaxel—skin cancer	0.000565	0.00143	CcSEcCtD
Orlistat—PNLIP—Metabolism—PLIN2—skin cancer	0.000563	0.00594	CbGpPWpGaD
Orlistat—Urinary tract disorder—Docetaxel—skin cancer	0.000562	0.00142	CcSEcCtD
Orlistat—Oedema peripheral—Docetaxel—skin cancer	0.000561	0.00142	CcSEcCtD
Orlistat—Oedema—Fluorouracil—skin cancer	0.000561	0.00142	CcSEcCtD
Orlistat—Anaphylactic shock—Fluorouracil—skin cancer	0.000561	0.00142	CcSEcCtD
Orlistat—Urethral disorder—Docetaxel—skin cancer	0.000558	0.00141	CcSEcCtD
Orlistat—Infection—Fluorouracil—skin cancer	0.000557	0.00141	CcSEcCtD
Orlistat—Feeling abnormal—Dactinomycin—skin cancer	0.000554	0.0014	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000554	0.0014	CcSEcCtD
Orlistat—Insomnia—Temozolomide—skin cancer	0.00055	0.00139	CcSEcCtD
Orlistat—Gastrointestinal pain—Dactinomycin—skin cancer	0.00055	0.00139	CcSEcCtD
Orlistat—Nervous system disorder—Fluorouracil—skin cancer	0.00055	0.00139	CcSEcCtD
Orlistat—FASN—AMPK Signaling—TP53—skin cancer	0.00055	0.0058	CbGpPWpGaD
Orlistat—Paraesthesia—Temozolomide—skin cancer	0.000546	0.00138	CcSEcCtD
Orlistat—PNLIP—Disease—CSPG4—skin cancer	0.000542	0.00572	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PTGER4—skin cancer	0.000536	0.00565	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PTGER4—skin cancer	0.000536	0.00565	CbGpPWpGaD
Orlistat—Dyspepsia—Temozolomide—skin cancer	0.000536	0.00135	CcSEcCtD
Orlistat—Body temperature increased—Dactinomycin—skin cancer	0.000532	0.00134	CcSEcCtD
Orlistat—Abdominal pain—Dactinomycin—skin cancer	0.000532	0.00134	CcSEcCtD
Orlistat—Hypersensitivity—Bleomycin—skin cancer	0.000531	0.00134	CcSEcCtD
Orlistat—Decreased appetite—Temozolomide—skin cancer	0.000529	0.00134	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—SHH—skin cancer	0.000527	0.00556	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—SHH—skin cancer	0.000527	0.00556	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Temozolomide—skin cancer	0.000525	0.00133	CcSEcCtD
Orlistat—Fatigue—Temozolomide—skin cancer	0.000525	0.00133	CcSEcCtD
Orlistat—Pain—Temozolomide—skin cancer	0.00052	0.00132	CcSEcCtD
Orlistat—Asthenia—Bleomycin—skin cancer	0.000518	0.00131	CcSEcCtD
Orlistat—Immune system disorder—Docetaxel—skin cancer	0.000514	0.0013	CcSEcCtD
Orlistat—Mediastinal disorder—Docetaxel—skin cancer	0.000513	0.0013	CcSEcCtD
Orlistat—PLA2G4A—Arachidonic acid metabolism—PTGS2—skin cancer	0.000513	0.00541	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000511	0.00129	CcSEcCtD
Orlistat—Pruritus—Bleomycin—skin cancer	0.00051	0.00129	CcSEcCtD
Orlistat—Insomnia—Fluorouracil—skin cancer	0.000507	0.00128	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000504	0.00532	CbGpPWpGaD
Orlistat—Paraesthesia—Fluorouracil—skin cancer	0.000503	0.00127	CcSEcCtD
Orlistat—Alopecia—Docetaxel—skin cancer	0.000503	0.00127	CcSEcCtD
Orlistat—Feeling abnormal—Temozolomide—skin cancer	0.000501	0.00127	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTCH2—skin cancer	0.000501	0.00529	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—SMO—skin cancer	0.0005	0.00527	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PTCH1—skin cancer	0.0005	0.00527	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTCH1—skin cancer	0.0005	0.00527	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—SMO—skin cancer	0.0005	0.00527	CbGpPWpGaD
Orlistat—Mental disorder—Docetaxel—skin cancer	0.000499	0.00126	CcSEcCtD
Orlistat—Gastrointestinal pain—Temozolomide—skin cancer	0.000498	0.00126	CcSEcCtD
Orlistat—Malnutrition—Docetaxel—skin cancer	0.000496	0.00125	CcSEcCtD
Orlistat—Hypersensitivity—Dactinomycin—skin cancer	0.000496	0.00125	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000494	0.00521	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000494	0.00521	CbGpPWpGaD
Orlistat—Dyspepsia—Fluorouracil—skin cancer	0.000494	0.00125	CcSEcCtD
Orlistat—Decreased appetite—Fluorouracil—skin cancer	0.000487	0.00123	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—PTGER4—skin cancer	0.000487	0.00514	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTGER4—skin cancer	0.000487	0.00514	CbGpPWpGaD
Orlistat—Dysgeusia—Docetaxel—skin cancer	0.000486	0.00123	CcSEcCtD
Orlistat—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000484	0.00122	CcSEcCtD
Orlistat—Urticaria—Temozolomide—skin cancer	0.000483	0.00122	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—skin cancer	0.000483	0.00122	CcSEcCtD
Orlistat—Abdominal pain—Temozolomide—skin cancer	0.000481	0.00122	CcSEcCtD
Orlistat—Body temperature increased—Temozolomide—skin cancer	0.000481	0.00122	CcSEcCtD
Orlistat—Back pain—Docetaxel—skin cancer	0.00048	0.00121	CcSEcCtD
Orlistat—Pain—Fluorouracil—skin cancer	0.000479	0.00121	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000478	0.00504	CbGpPWpGaD
Orlistat—Muscle spasms—Docetaxel—skin cancer	0.000477	0.00121	CcSEcCtD
Orlistat—Feeling abnormal—Fluorouracil—skin cancer	0.000462	0.00117	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—skin cancer	0.00046	0.00116	CcSEcCtD
Orlistat—Vomiting—Bleomycin—skin cancer	0.000459	0.00116	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—GLI2—skin cancer	0.000458	0.00484	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GLI2—skin cancer	0.000458	0.00484	CbGpPWpGaD
Orlistat—Rash—Bleomycin—skin cancer	0.000455	0.00115	CcSEcCtD
Orlistat—Dermatitis—Bleomycin—skin cancer	0.000454	0.00115	CcSEcCtD
Orlistat—PNLIP—Metabolism—CSPG4—skin cancer	0.000454	0.00479	CbGpPWpGaD
Orlistat—Hypersensitivity—Temozolomide—skin cancer	0.000448	0.00113	CcSEcCtD
Orlistat—Urticaria—Fluorouracil—skin cancer	0.000445	0.00113	CcSEcCtD
Orlistat—Body temperature increased—Fluorouracil—skin cancer	0.000443	0.00112	CcSEcCtD
Orlistat—Palpitations—Docetaxel—skin cancer	0.000438	0.00111	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—MC1R—skin cancer	0.000437	0.00461	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MC1R—skin cancer	0.000437	0.00461	CbGpPWpGaD
Orlistat—Asthenia—Temozolomide—skin cancer	0.000437	0.0011	CcSEcCtD
Orlistat—Cough—Docetaxel—skin cancer	0.000433	0.00109	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—GLI1—skin cancer	0.000431	0.00455	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GLI1—skin cancer	0.000431	0.00455	CbGpPWpGaD
Orlistat—Pruritus—Temozolomide—skin cancer	0.000431	0.00109	CcSEcCtD
Orlistat—Convulsion—Docetaxel—skin cancer	0.00043	0.00109	CcSEcCtD
Orlistat—Nausea—Bleomycin—skin cancer	0.000428	0.00108	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—skin cancer	0.000428	0.00108	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000425	0.00448	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000425	0.00448	CbGpPWpGaD
Orlistat—Rash—Dactinomycin—skin cancer	0.000424	0.00107	CcSEcCtD
Orlistat—Chest pain—Docetaxel—skin cancer	0.000422	0.00107	CcSEcCtD
Orlistat—Myalgia—Docetaxel—skin cancer	0.000422	0.00107	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000419	0.00106	CcSEcCtD
Orlistat—Diarrhoea—Temozolomide—skin cancer	0.000416	0.00105	CcSEcCtD
Orlistat—Hypersensitivity—Fluorouracil—skin cancer	0.000413	0.00104	CcSEcCtD
Orlistat—Dry mouth—Docetaxel—skin cancer	0.000413	0.00104	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SUFU—skin cancer	0.000408	0.00431	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SUFU—skin cancer	0.000408	0.00431	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	0.000406	0.00428	CbGpPWpGaD
Orlistat—Oedema—Docetaxel—skin cancer	0.000405	0.00102	CcSEcCtD
Orlistat—Anaphylactic shock—Docetaxel—skin cancer	0.000405	0.00102	CcSEcCtD
Orlistat—Dizziness—Temozolomide—skin cancer	0.000402	0.00102	CcSEcCtD
Orlistat—Infection—Docetaxel—skin cancer	0.000402	0.00102	CcSEcCtD
Orlistat—Nausea—Dactinomycin—skin cancer	0.0004	0.00101	CcSEcCtD
Orlistat—FASN—Metabolism—PLIN2—skin cancer	0.000399	0.00421	CbGpPWpGaD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—skin cancer	0.000397	0.00419	CbGpPWpGaD
Orlistat—Nervous system disorder—Docetaxel—skin cancer	0.000397	0.001	CcSEcCtD
Orlistat—Pruritus—Fluorouracil—skin cancer	0.000397	0.001	CcSEcCtD
Orlistat—Skin disorder—Docetaxel—skin cancer	0.000393	0.000994	CcSEcCtD
Orlistat—Vomiting—Temozolomide—skin cancer	0.000387	0.000978	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000384	0.00405	CbGpPWpGaD
Orlistat—Rash—Temozolomide—skin cancer	0.000384	0.00097	CcSEcCtD
Orlistat—Diarrhoea—Fluorouracil—skin cancer	0.000384	0.00097	CcSEcCtD
Orlistat—FASN—Disease—CSPG4—skin cancer	0.000384	0.00405	CbGpPWpGaD
Orlistat—Dermatitis—Temozolomide—skin cancer	0.000383	0.000969	CcSEcCtD
Orlistat—Headache—Temozolomide—skin cancer	0.000381	0.000964	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—GLI2—skin cancer	0.00038	0.00401	CbGpPWpGaD
Orlistat—Dizziness—Fluorouracil—skin cancer	0.000371	0.000937	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000369	0.000932	CcSEcCtD
Orlistat—PNLIP—Disease—ENO2—skin cancer	0.000369	0.00389	CbGpPWpGaD
Orlistat—PNLIP—Disease—SHH—skin cancer	0.000369	0.00389	CbGpPWpGaD
Orlistat—Insomnia—Docetaxel—skin cancer	0.000366	0.000925	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—skin cancer	0.000363	0.000919	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—MC1R—skin cancer	0.000362	0.00382	CbGpPWpGaD
Orlistat—Nausea—Temozolomide—skin cancer	0.000361	0.000914	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000361	0.00381	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000361	0.00381	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—GLI1—skin cancer	0.000357	0.00377	CbGpPWpGaD
Orlistat—Vomiting—Fluorouracil—skin cancer	0.000356	0.000901	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—skin cancer	0.000356	0.0009	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—HRAS—skin cancer	0.000356	0.00376	CbGpPWpGaD
Orlistat—Rash—Fluorouracil—skin cancer	0.000353	0.000894	CcSEcCtD
Orlistat—Dermatitis—Fluorouracil—skin cancer	0.000353	0.000893	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—skin cancer	0.000352	0.000889	CcSEcCtD
Orlistat—Headache—Fluorouracil—skin cancer	0.000351	0.000888	CcSEcCtD
Orlistat—Gastrointestinal disorder—Docetaxel—skin cancer	0.000349	0.000883	CcSEcCtD
Orlistat—Fatigue—Docetaxel—skin cancer	0.000349	0.000882	CcSEcCtD
Orlistat—Pain—Docetaxel—skin cancer	0.000346	0.000875	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000346	0.00365	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000346	0.00365	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SUFU—skin cancer	0.000338	0.00357	CbGpPWpGaD
Orlistat—Feeling abnormal—Docetaxel—skin cancer	0.000333	0.000843	CcSEcCtD
Orlistat—Nausea—Fluorouracil—skin cancer	0.000333	0.000842	CcSEcCtD
Orlistat—Gastrointestinal pain—Docetaxel—skin cancer	0.000331	0.000836	CcSEcCtD
Orlistat—FASN—Metabolism—CSPG4—skin cancer	0.000321	0.00339	CbGpPWpGaD
Orlistat—Body temperature increased—Docetaxel—skin cancer	0.00032	0.000809	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—skin cancer	0.00032	0.000809	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—SHH—skin cancer	0.000311	0.00329	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RHOU—skin cancer	0.000311	0.00329	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SHH—skin cancer	0.000311	0.00329	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RASA1—skin cancer	0.000309	0.00327	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RASA1—skin cancer	0.000309	0.00327	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ENO2—skin cancer	0.000309	0.00326	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—BRAF—skin cancer	0.000305	0.00322	CbGpPWpGaD
Orlistat—PNLIP—Disease—FOXO4—skin cancer	0.0003	0.00317	CbGpPWpGaD
Orlistat—Hypersensitivity—Docetaxel—skin cancer	0.000298	0.000754	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SMO—skin cancer	0.000295	0.00312	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SMO—skin cancer	0.000295	0.00312	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTCH1—skin cancer	0.000295	0.00312	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTCH1—skin cancer	0.000295	0.00312	CbGpPWpGaD
Orlistat—Asthenia—Docetaxel—skin cancer	0.00029	0.000734	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PTGER4—skin cancer	0.000287	0.00303	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTGER4—skin cancer	0.000287	0.00303	CbGpPWpGaD
Orlistat—Pruritus—Docetaxel—skin cancer	0.000286	0.000724	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—skin cancer	0.000277	0.0007	CcSEcCtD
Orlistat—Dizziness—Docetaxel—skin cancer	0.000268	0.000676	CcSEcCtD
Orlistat—FASN—Disease—SHH—skin cancer	0.000261	0.00275	CbGpPWpGaD
Orlistat—FASN—Disease—ENO2—skin cancer	0.000261	0.00275	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SHH—skin cancer	0.000258	0.00272	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTCH2—skin cancer	0.000257	0.00272	CbGpPWpGaD
Orlistat—Vomiting—Docetaxel—skin cancer	0.000257	0.00065	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—RASA1—skin cancer	0.000256	0.00271	CbGpPWpGaD
Orlistat—Rash—Docetaxel—skin cancer	0.000255	0.000645	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—skin cancer	0.000255	0.000644	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—FOXO4—skin cancer	0.000254	0.00268	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FOXO4—skin cancer	0.000254	0.00268	CbGpPWpGaD
Orlistat—Headache—Docetaxel—skin cancer	0.000254	0.000641	CcSEcCtD
Orlistat—DAGLA—Hemostasis—NRAS—skin cancer	0.000249	0.00263	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NRAS—skin cancer	0.000249	0.00263	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	0.000249	0.00263	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000246	0.00259	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTCH1—skin cancer	0.000245	0.00258	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMO—skin cancer	0.000245	0.00258	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—HRAS—skin cancer	0.000243	0.00256	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000241	0.00255	CbGpPWpGaD
Orlistat—Nausea—Docetaxel—skin cancer	0.00024	0.000608	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTGER4—skin cancer	0.000238	0.00251	CbGpPWpGaD
Orlistat—FASN—Metabolism—ENO2—skin cancer	0.000218	0.0023	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KRAS—skin cancer	0.000214	0.00226	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—KRAS—skin cancer	0.000214	0.00226	CbGpPWpGaD
Orlistat—PNLIP—Disease—ERCC2—skin cancer	0.000214	0.00226	CbGpPWpGaD
Orlistat—FASN—Disease—FOXO4—skin cancer	0.000213	0.00224	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FOXO4—skin cancer	0.00021	0.00222	CbGpPWpGaD
Orlistat—PNLIP—Disease—TERT—skin cancer	0.000201	0.00212	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—skin cancer	0.000192	0.00202	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—skin cancer	0.00019	0.00201	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—skin cancer	0.00019	0.00201	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MC1R—skin cancer	0.000186	0.00196	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—skin cancer	0.000182	0.00192	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—skin cancer	0.000182	0.00192	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ERCC2—skin cancer	0.000179	0.00189	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000175	0.00185	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLIN2—skin cancer	0.000171	0.0018	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000171	0.0018	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TERT—skin cancer	0.00017	0.00179	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TERT—skin cancer	0.00017	0.00179	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—skin cancer	0.000165	0.00174	CbGpPWpGaD
Orlistat—PNLIP—Disease—BRAF—skin cancer	0.000159	0.00168	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTCH2—skin cancer	0.000152	0.00161	CbGpPWpGaD
Orlistat—FASN—Disease—ERCC2—skin cancer	0.000151	0.0016	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—skin cancer	0.000143	0.00151	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—NRAS—skin cancer	0.000143	0.00151	CbGpPWpGaD
Orlistat—FASN—Disease—TERT—skin cancer	0.000142	0.0015	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TERT—skin cancer	0.000141	0.00148	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—skin cancer	0.00014	0.00148	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CSPG4—skin cancer	0.000138	0.00145	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BRAF—skin cancer	0.000134	0.00142	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BRAF—skin cancer	0.000134	0.00142	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SHH—skin cancer	0.000133	0.0014	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—skin cancer	0.000128	0.00135	CbGpPWpGaD
Orlistat—FASN—Metabolism—ERCC2—skin cancer	0.000127	0.00134	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTCH1—skin cancer	0.000126	0.00133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SMO—skin cancer	0.000126	0.00133	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—skin cancer	0.000123	0.0013	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—skin cancer	0.000123	0.0013	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTGER4—skin cancer	0.000122	0.00129	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000118	0.00124	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GLI2—skin cancer	0.000115	0.00122	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—skin cancer	0.000112	0.00119	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—skin cancer	0.000111	0.00117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MC1R—skin cancer	0.00011	0.00116	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GLI1—skin cancer	0.000108	0.00114	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—skin cancer	0.000107	0.00113	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—skin cancer	0.000105	0.0011	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—skin cancer	0.000105	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000104	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SUFU—skin cancer	0.000103	0.00108	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—skin cancer	0.0001	0.00106	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—skin cancer	0.0001	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—skin cancer	9.99e-05	0.00105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO2—skin cancer	9.37e-05	0.000989	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—skin cancer	9.08e-05	0.000958	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—skin cancer	8.6e-05	0.000907	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—skin cancer	8.44e-05	0.000891	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—skin cancer	8.44e-05	0.000891	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SHH—skin cancer	7.84e-05	0.000827	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RASA1—skin cancer	7.79e-05	0.000822	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—skin cancer	7.61e-05	0.000803	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMO—skin cancer	7.43e-05	0.000784	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTCH1—skin cancer	7.43e-05	0.000784	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.33e-05	0.000773	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—skin cancer	7.31e-05	0.000771	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—skin cancer	7.26e-05	0.000767	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—skin cancer	7.26e-05	0.000767	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTGER4—skin cancer	7.23e-05	0.000763	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—skin cancer	7.07e-05	0.000746	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—skin cancer	6.99e-05	0.000738	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—skin cancer	6.99e-05	0.000738	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—skin cancer	6.46e-05	0.000681	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—skin cancer	6.46e-05	0.000681	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FOXO4—skin cancer	6.39e-05	0.000674	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—skin cancer	6.26e-05	0.000661	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—skin cancer	6.17e-05	0.000652	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—skin cancer	6.17e-05	0.000652	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—skin cancer	6.08e-05	0.000642	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—skin cancer	6.02e-05	0.000635	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—skin cancer	5.91e-05	0.000624	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—skin cancer	5.91e-05	0.000624	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ERCC2—skin cancer	5.44e-05	0.000574	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—skin cancer	5.39e-05	0.000569	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—skin cancer	5.35e-05	0.000565	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—skin cancer	5.17e-05	0.000546	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—skin cancer	5.12e-05	0.00054	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—skin cancer	4.95e-05	0.000522	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—skin cancer	4.9e-05	0.000517	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—skin cancer	4.79e-05	0.000506	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—skin cancer	4.58e-05	0.000484	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—skin cancer	4.27e-05	0.00045	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLIN2—skin cancer	4.01e-05	0.000423	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—skin cancer	3.59e-05	0.000379	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—skin cancer	3.38e-05	0.000357	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—skin cancer	3.26e-05	0.000344	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CSPG4—skin cancer	3.23e-05	0.000341	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—skin cancer	3.09e-05	0.000326	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—skin cancer	2.63e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—skin cancer	2.52e-05	0.000266	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—skin cancer	2.19e-05	0.000232	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—skin cancer	2.12e-05	0.000224	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—skin cancer	1.83e-05	0.000193	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—skin cancer	1.62e-05	0.000171	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—skin cancer	1.55e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—skin cancer	1.49e-05	0.000157	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ERCC2—skin cancer	1.27e-05	0.000135	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—skin cancer	7.64e-06	8.07e-05	CbGpPWpGaD
